HDAC Inhibitors Market to Hit $7.5 Billion by 2036 as New Approvals Drive 10% CAGR
Updated
Updated · futuremarketinsights.com · Aug 22
HDAC Inhibitors Market to Hit $7.5 Billion by 2036 as New Approvals Drive 10% CAGR
1 articles · Updated · futuremarketinsights.com · Aug 22
Summary
$7.5 billion is the projected size of the HDAC inhibitors market by 2036, up from $2.9 billion in 2026, with demand forecast to grow at a 10.0% annual rate.
New approvals beyond lymphoma are widening use in specialist care, including FDA approval of oral givinostat in March 2024 and China’s April 2024 approval of chidamide plus R-CHOP in a defined first-line DLBCL group.
Access still diverges after approval: Japan has established tucidinostat use, while Germany requires benefit assessment and price talks for givinostat, and France issued an unfavorable reimbursement opinion in February 2026.
In 2026, pan-HDAC inhibitors are expected to hold 44.0% of product demand, hematologic malignancies 41.0% of applications, and oral products 63.0% of administration revenue.
The outlook remains tied to whether developers can show comparative benefit and manage toxicity, as monitoring requirements and payer evidence demands may limit eligible populations and slow reimbursement.